DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
CENTER FOR DRUG EVALUATION AND RESEARCH

Division of Quality Surveillance Assessment
Inspection Assessment Branch
10903 New Hampshire Avenue
Building #51, Room 4316
Silver Spring, MD 20993

TELEPHONE: (301) 796-3254
FAX: (301) 847-8742

February 01, 2016

Ms. Wang Fang
CEO
Chongqing Carelife Pharmaceutical Co.,
3 Hua Nanyi Road
Chongqing Chemical Industry Park
Chongqing, P.R. China 401221

Reference FEI 3005256542
Reference inspection date (s): 09/21/2015 - 09/25/2015
Establishment Locale: China

Dear Ms. Wang Fang:

We are enclosing a copy of the establishment inspection report (EIR) for the inspection that the U.S. Food and Drug Administration (FDA) conducted at your premises on the referenced locale and date(s). When the Agency concludes that an inspection is "closed" under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment. This procedure is applicable to EIRs for inspections completed on or after April 1, 1997.

The Agency continually works to make its regulatory process and activities more transparent to the regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting additional information under FOIA.

If there is any question about the released information, feel free to contact me at the above address or number.

Sincerely,

Rhoda B. Eniafe -S

Digitally signed by Rhoda B. Eniafe -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=00100695 87, cn=Rhoda B. Eniafe -S
Date: 2016.02.01 09:30:09 -05'00'

Concepcion Cruz
Supervisory Consumer Safety
Inspection Assessment Branch

Enclosure: EIR